Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lutetium Lu 177 Vipivotide Tetraxetan · Pluvicto, AAA617

Radiopharmaceutical · Kills target cells, directed at prostate-specific membrane antigen (PSMA) (FOLH1) · developed by Novartis

Approved FDA, Mar 2022
NVS Developer
2 Registered trials

What is Lutetium Lu 177 Vipivotide Tetraxetan?

Lutetium Lu 177 vipivotide tetraxetan is a radioligand that pairs the beta-emitting radionuclide lutetium-177 with a PSMA-binding ligand. It binds PSMA-expressing cells, where beta radiation damages DNA and kills the cells, including nearby cells. It is studied in metastatic castration-resistant and other prostate cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pluvicto, AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Drug type
Radiopharmaceutical
Targets
prostate-specific membrane antigen (PSMA) (FOLH1)
Mechanism
Kills target cells, directed at prostate-specific membrane antigen (PSMA) (FOLH1)
Pathways
DNA damage, cell death
Therapy area
Oncology
Developer
Novartis (NVS)
FDA status
Approved as Pluvicto (March 23, 2022), NDA215833 · FDA label
UNII
G6UF363ECX

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 12, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06894511 Phase 2 Metastatic Castration Resistant Prostate Cancer (mCRPC) Active not recruiting NVS
NCT06943495 Phase 1 Metastatic Castrate Resistant Prostate Cancer (mCRPC) Recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Prostate CancerProstate Cancer

Other drugs acting on FOLH1

More from Novartis

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Lutetium Lu 177 Vipivotide Tetraxetan

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.